Radian Group Inc (NYSE:RDN) net profit announced that the underwriters of its recently announced public offering of common stock have exercised in full their option to purchase an additional 2,325,000 shares of common stock from Radian Group at the public offering price of $14.50 per share, less underwriting discounts and commissions. As a result, Radian Group expects to issue a total of 17,825,000 shares of common stock in the offering. Goldman, Sachs & Co. acted as book-running manager for the offering, and J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Keefe, Bruyette & Woods, Inc., and Macquarie Capital (USA) Inc. acted as co-managers. Radian Group Inc (NYSE:RDN) net profit margin is -26.00% and weekly performance is 5.29%. On last trading day company shares ended up $14.72. Analysts mean target price for the company is $17.28. Radian Group Inc (NYSE:RDN) distance from 50-day simple moving average (SMA50) is -0.63%.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer, will present at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas on Wednesday, May 14th at 4:20pm PT and Jean-Jacques Bienaime, Chief Executive Officer, will present at the UBS Global Healthcare Conference in New York on Tuesday, May 20th at 8:00am ET. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares fell -2.92% in last trading session and ended the day on $56.78. BMRN Gross Margin is 82.60% and its return on assets is -10.00%. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) quarterly performance is -12.63%.
The Fresh Market Inc (NASDAQ:TFM) stock was downgraded to “underperform” from “neutral” by analysts at Sterne Agee before the opening bell today. The Fresh Market Inc (NASDAQ:TFM) shares moved down -0.28% in last trading session and was closed at $32.02, while trading in range of $31.80 – 33.10. The Fresh Market Inc (NASDAQ:TFM) year to date (YTD) performance is -20.94%.
On May 6, the board of directors of Cree, Inc. (NASDAQ:CREE) approved an increase in the amount of the company’s stock repurchase program. Pursuant to the program, the company is now authorized to repurchase shares of its common stock having an aggregate purchase price not exceeding $300M for all purchases from June 20, 2013 through the new expiration of the program on June 28, 2015. Cree, Inc. (NASDAQ:CREE) ended the last trading day at $45.40. Company weekly volatility is calculated as 3.38% and price to cash ratio as 132.46. Cree, Inc. (NASDAQ:CREE) showed a negative weekly performance of -14.41%.